BRTX Discloses Preliminary Phase 2 Clinical Trial Results via 8-K
Ticker: BRTX · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1505497
Complexity: simple
Sentiment: neutral
Topics: clinical-trial, biotech, regulation-fd, press-release
TL;DR
**BRTX just dropped preliminary Phase 2 trial results, watch for market reaction!**
AI Summary
BioRestorative Therapies, Inc. (BRTX) filed an 8-K on February 1, 2024, to disclose a press release regarding preliminary results from its Phase 2 clinical trial. This filing, under Regulation FD Disclosure, indicates the company is sharing important, non-public information about its clinical progress. For investors, this matters because positive preliminary trial results could significantly boost the stock price by demonstrating the potential efficacy and safety of their therapeutic candidates, while negative or inconclusive results could have the opposite effect.
Why It Matters
This filing signals that BioRestorative Therapies is releasing crucial information about its drug development, which can directly impact investor sentiment and stock valuation based on the trial's outcome.
Risk Assessment
Risk Level: medium — Clinical trial results are inherently high-risk events for biotech companies, but this filing only discloses the *release* of results, not the results themselves, making the immediate risk medium.
Analyst Insight
A smart investor would seek out the actual press release mentioned in this 8-K to understand the preliminary Phase 2 clinical trial results and assess their implications for BRTX's future prospects before making any investment decisions.
Key Players & Entities
- BioRestorative Therapies, Inc. (company) — the registrant filing the 8-K
- BRTX (company) — the trading symbol for BioRestorative Therapies, Inc.
- February 1, 2024 (date) — the date of the earliest event reported and filing date
- NASDAQ Capital Market (company) — the exchange where BRTX Common Stock is registered
Forward-Looking Statements
- The stock price of BRTX will experience significant volatility following the full release of the preliminary Phase 2 clinical trial results. (BRTX) — high confidence, target: 2024-02-08
FAQ
What is the primary purpose of this 8-K filing by BioRestorative Therapies, Inc.?
The primary purpose of this 8-K filing, dated February 1, 2024, is to disclose a press release concerning preliminary results from a Phase 2 clinical trial, under Item 7.01 Regulation FD Disclosure.
What is the trading symbol and exchange for BioRestorative Therapies, Inc.?
BioRestorative Therapies, Inc. trades under the symbol BRTX on the NASDAQ Capital Market, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934'.
What is the business address and phone number of BioRestorative Therapies, Inc.?
The business address for BioRestorative Therapies, Inc. is 40 Marcus Drive, Melville, New York, 11747, and their telephone number is (631) 760-8100, according to the filing's business address section.
Under which item of Form 8-K was this disclosure made?
This disclosure was made under 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits', specifically Item 7.01 and Item 9.01, respectively, as indicated in the filing.
Has BioRestorative Therapies, Inc. undergone a name change in the past?
Yes, the filing indicates that BioRestorative Therapies, Inc. was formerly known as Stem Cell Assurance, Inc., with the date of name change being November 10, 2010.
Filing Stats: 620 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-02-01 16:43:48
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value BRTX NASDAQ Capital Marke
Filing Documents
- bio8k2124.htm (8-K) — 25KB
- ex99_1.htm (EX-99.1) — 1KB
- image00001.jpg (GRAPHIC) — 1009KB
- image00002.jpg (GRAPHIC) — 615KB
- 0001021771-24-000025.txt ( ) — 2394KB
- brtx-20240201.xsd (EX-101.SCH) — 4KB
- brtx-20240201_lab.xml (EX-101.LAB) — 22KB
- brtx-20240201_pre.xml (EX-101.PRE) — 16KB
- bio8k2124_htm.xml (XML) — 4KB
01
Item 7.01 Regulation FD Disclosure . On February 1, 2024, BioRestorative Therapies, Inc. (the "Company") issued a press release (the "Press Release") announcing that preliminary 26–52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease will be presented at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, taking place February 2-6, 2024 in Long Beach, California. In the Press Release, the Company also announced that it will hold a webcasted conference call with an associated slide presentation on February 5, 2024 at 8:30 a.m. ET to review the BRTX-100 poster. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information in the Press Release is being furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Press Release will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Report with respect to the Press Release is not intended to, and does not, constitute a determination or admission by the Company that the information in this Report with respect to the Press Release is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
Financial Statements and Exhibits
Financial Statements and Exhibits . (d) Exhibits . Number Description 99.1 Press release, dated February 1, 2024, issued by BioRestorative Therapies, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIORESTORATIVE THERAPIES, INC. Dated: February 1, 2024 By: /s/ Lance Alstodt Lance Alstodt President and CEO